Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Huya Bioscience International, a pharmaceutical co-development company, has signed a partnership agreement with the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College.
Subscribe to our email newsletter
The agreement grants Huya the opportunity to collaborate with The Beijing Institute of Materia Medica (BIMM) on preclinical safety and efficacy, and clinical trial protocols.
The agreement also provides Huya with the right of first review and negotiation for the licensing and development of certain new compounds owned or controlled by BIMM. This right includes drugs in discovery and development for use in the areas of cardiology, endocrinology, oncology, immunology, hematology, neuroscience and anti-infectives.
Huya currently has two Chinese drugs undergoing preclinical development in the US – HBI-3000 and HBI-8000. Both drugs, for cardiac fibrillation and oncology respectively, have successfully passed the FDA pre-investigational new drug-consultations.
Mireille Gingras, CEO of Huya, said: Huya is highly experienced and uniquely positioned in China to leverage the emerging biotech industry through strong collaborations. This is the culmination of years of relationship-building and exchange of knowledge between Huya and BIMM. We are proud that the Institute of Materia Medica is our official partner and together we hope to bring new drugs to market.